PTH-related protein-(107-139) [PTHrP-(107-139)] has been reported prev
iously to be a potent inhibitor of osteoclast activity. However, this
finding has not been reproduced in other in vitro models. We have now
examined the effects of this peptide in an in vivo model, employing in
tact adult mice. Four groups of eight male mice were given injections
of either vehicle or one of three doses of PTHrP-(107-139) (4 x 10(-13
), 4 x 10(-11), or 4 x 10(-9) mel) over the periosteum of the right he
micalvaria for 5 consecutive days. The animals were killed 1 week afte
r the last injection. There were significant decreases in bone resorpt
ion indexes after all doses of PTHrP-(107-139), with a 70% decrease in
osteoclast number (P < 0.001), a 70% decrease in osteoclast perimeter
(P = 0.004), and a 50% decrease in eroded perimeter (P = 0.001). In a
ddition, some indexes of bone formation were significantly decreased,
with 40% decreases in both osteoblast number (P = 0.05) and osteoblast
perimeter (P = 0.02), but no significant change in osteoid area. Ther
e was a dose-related upward trend in mineralized bone area, reaching 1
2% at the highest dose, but this was not statistically significant. It
is concluded that PTHrP-(107-139) is a potent inhibitor of bone resor
ption in vivo. As this model is very dissimilar to that of isolated os
teoclasts, in which this peptide is also active, the present findings
suggest that osteoclast inhibition is an authentic action of the C-ter
minus of PTHrP, which may, therefore, play a role in the regulation of
bone turnover in vivo.